Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Hear the latest updates in thoracic oncology from leading experts at the British Thoracic Oncology Group (BTOG) 2023 Annual Conference. Visit BTOG.org to find out more and to register.
View all videos

BTOG 2023

21st BTOG Annual Conference 2023
26–28 April 2023 | Belfast, UK

🎥@AlexisLevee of @CityofHope discusses a study on gut microbiome's link to response in metastatic #breastcancer treated with ICIs. Future studies aim to personalize treatments and develop probiotics:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #ImmunoOnc #BCsm

Image for twitter card

Using gut microbiota to enhance immunotherapy for breast cancer

Alexis Ann LeVee, MD, City of Hope, Duarte, CA, comments on a Phase I/II study (NCT02778685) that revealed the g...

ow.ly

🎥@drlauragoff of @VUMC_Cancer discusses the CheckMate 9DW trial, showing nivolumab + ipilimumab improved OS in advanced HCC vs. sorafenib or lenvatinib, outperforming IMbrave150 and HIMALAYA trials:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #CTSM #ImmunoOnc #HPBCsm

Image for twitter card

CheckMate 9DW: the future of checkpoint inhibitors in advanced HCC

Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides insight on the CheckMate ...

ow.ly

Load More

BTOG 2023

21st BTOG Annual Conference 2023
26–28 April 2023 | Belfast, UK
Hear the latest updates in thoracic oncology from leading experts at the British Thoracic Oncology Group (BTOG) 2023 Annual Conference. Visit BTOG.org to find out more and to register.
View all videos

🎥@AlexisLevee of @CityofHope discusses a study on gut microbiome's link to response in metastatic #breastcancer treated with ICIs. Future studies aim to personalize treatments and develop probiotics:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #ImmunoOnc #BCsm

Image for twitter card

Using gut microbiota to enhance immunotherapy for breast cancer

Alexis Ann LeVee, MD, City of Hope, Duarte, CA, comments on a Phase I/II study (NCT02778685) that revealed the g...

ow.ly

🎥@drlauragoff of @VUMC_Cancer discusses the CheckMate 9DW trial, showing nivolumab + ipilimumab improved OS in advanced HCC vs. sorafenib or lenvatinib, outperforming IMbrave150 and HIMALAYA trials:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #CTSM #ImmunoOnc #HPBCsm

Image for twitter card

CheckMate 9DW: the future of checkpoint inhibitors in advanced HCC

Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides insight on the CheckMate ...

ow.ly

Load More